A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard FDA Approved Therapy With Sipuleucel-T (Provenge) for Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer (mCRPC)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-7 (Primary) ; Sipuleucel-T
- Indications Prostate cancer
- Focus Therapeutic Use
- 09 Jul 2019 Biomarkers information updated
- 03 Dec 2013 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 03 Dec 2013 Planned initiation date changed from 1 Jul 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.